MHRA approves new oral treatment for moderate to severe plaque psoriasis

Synopsis

MHRA approves new oral treatment for moderate to severe plaque psoriasis The Medicines and Healthcare products Regulatory Agency (MHRA) has approved icotrokinra hydrochloride (Icotyde) for the treatment of moderate to severe plaque psoriasis in adults and adolescents aged 12 years and older who weigh at least 40 kg and are candidates for systemic therapy.

Automatically extracted from the original page. This is a short summary, not the full story, and may omit important detail.